Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biopharmx Corp stock logo
BPMX
Biopharmx
$0.00
$0.25
$6.30
$111.86MN/A2.15 million shs336,508 shs
(COV) stock logo
COV
(COV)
$0.00
$65.97
$108.57
N/AN/A3.88 million shsN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
$81.21
+1.1%
$79.75
$65.18
$82.62
$158.36M1.225,107 shs4,871 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biopharmx Corp stock logo
BPMX
Biopharmx
0.00%0.00%0.00%0.00%0.00%
(COV) stock logo
COV
(COV)
0.00%0.00%0.00%0.00%0.00%
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
+1.11%+2.85%-0.43%+6.35%+22.45%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
0.00
N/A$87.938.27% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/A11.93N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
$1.481.82%N/AN/AN/A

Latest 4BB, FAB, BPMX, HVO, and COV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/20/2024
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
Quarterly$0.24303/21/20243/22/20243/28/2024
(Data available from 1/1/2013 forward)

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
(COV) stock logo
COV
(COV)
N/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/A

Insider Ownership

CompanyInsider Ownership
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
(COV) stock logo
COV
(COV)
N/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biopharmx Corp stock logo
BPMX
Biopharmx
1718.28 millionN/ANot Optionable
(COV) stock logo
COV
(COV)
N/AN/AN/ANot Optionable
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
147,0001.95 millionN/ANot Optionable

4BB, FAB, BPMX, HVO, and COV Headlines

SourceHeadline
First Trust Multi Cap Value AlphaDEX Fund (NASDAQ:FAB)  Shares Down 0.3% First Trust Multi Cap Value AlphaDEX Fund (NASDAQ:FAB) Shares Down 0.3%
americanbankingnews.com - May 2 at 2:00 AM
First Trust Multi Cap Value AlphaDEX Fund (NASDAQ:FAB) Short Interest Up 200.0% in MarchFirst Trust Multi Cap Value AlphaDEX Fund (NASDAQ:FAB) Short Interest Up 200.0% in March
marketbeat.com - April 10 at 4:43 PM
First Trust Mid Cap Core AlphaDEX® Fund declares $0.4394 dividendFirst Trust Mid Cap Core AlphaDEX® Fund declares $0.4394 dividend
msn.com - December 22 at 1:05 PM
First Trust Multi Cap Growth AlphaDEX FundFirst Trust Multi Cap Growth AlphaDEX Fund
wsj.com - May 18 at 10:40 PM
FAB First Trust Multi Cap Value AlphaDEX® Fund ETFFAB First Trust Multi Cap Value AlphaDEX® Fund ETF
seekingalpha.com - April 28 at 8:40 AM
First Trust Exchange-Traded AlphaDEX Fund - First Trust Large Cap Growth AlphaDEX Fund (NASDAQ: FTC)First Trust Exchange-Traded AlphaDEX Fund - First Trust Large Cap Growth AlphaDEX Fund (NASDAQ: FTC)
fool.com - January 7 at 1:29 PM
First Trust Brazil AlphaDEX Fund declares quarterly distribution of $0.1018First Trust Brazil AlphaDEX Fund declares quarterly distribution of $0.1018
msn.com - December 23 at 1:31 PM
First Trust Multi Cap Value AlphaDEX Fund declares quarterly distribution of $0.4778First Trust Multi Cap Value AlphaDEX Fund declares quarterly distribution of $0.4778
msn.com - December 23 at 1:31 PM
Analysts See 28% Upside For The Holdings of FABAnalysts See 28% Upside For The Holdings of FAB
nasdaq.com - September 23 at 7:25 AM
Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?
finance.yahoo.com - August 22 at 8:36 AM
Surprising Analyst 12-Month Target For FABSurprising Analyst 12-Month Target For FAB
nasdaq.com - July 24 at 6:04 PM
Third Avenue Small-Cap Value Fund Q1 2022 Portfolio Manager CommentaryThird Avenue Small-Cap Value Fund Q1 2022 Portfolio Manager Commentary
seekingalpha.com - May 25 at 1:27 AM
First Trust Multi Cap Value AlphaDEX Fund declares quarterly distribution of $0.2096First Trust Multi Cap Value AlphaDEX Fund declares quarterly distribution of $0.2096
seekingalpha.com - March 25 at 5:05 PM
Analysts Predict 16% Gains Ahead For The Holdings of FABAnalysts Predict 16% Gains Ahead For The Holdings of FAB
nasdaq.com - March 4 at 8:18 AM
Implied FAB Analyst Target Price: $86Implied FAB Analyst Target Price: $86
nasdaq.com - February 10 at 9:52 AM
First Trust Multi Cap Value AlphaDEX Fund (FAB)First Trust Multi Cap Value AlphaDEX Fund (FAB)
nasdaq.com - January 22 at 7:59 PM
Implied FAB Analyst Target Price: $84Implied FAB Analyst Target Price: $84
nasdaq.com - January 12 at 10:54 AM
Peek Under The Hood: FAB Has 11% UpsidePeek Under The Hood: FAB Has 11% Upside
nasdaq.com - January 4 at 2:27 PM
How The Parts Add Up: FAB Headed For $83How The Parts Add Up: FAB Headed For $83
nasdaq.com - November 15 at 12:34 PM

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Biopharmx logo

Biopharmx

NYSEAMERICAN:BPMX
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
(COV) logo

(COV)

NYSE:COV
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
First Trust Multi Cap Value AlphaDEX Fund logo

First Trust Multi Cap Value AlphaDEX Fund

NASDAQ:FAB
The First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.